Cargando…
Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement
Autores principales: | Bedics, Gábor, Csóka, Monika, Reiniger, Lilla, Varga, Edit, Liptai, Zoltán, Papp, Gergő, Bekő, Anna, Cervi, Catherine, Bödör, Csaba, Scheich, Bálint |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807475/ https://www.ncbi.nlm.nih.gov/pubmed/36416966 http://dx.doi.org/10.1007/s00401-022-02520-6 |
Ejemplares similares
-
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas
por: Bedics, Gábor, et al.
Publicado: (2023) -
Germline
MUTYH
mutations and high‐grade gliomas: Novel evidence for a potential association
por: Bedics, Gábor, et al.
Publicado: (2022) -
Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023) -
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease
por: Váradi, Zsófia, et al.
Publicado: (2017) -
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)